Cardiometabolic Disease
Pelacarsen and lipoprotein(a) apheresis in secondary prevention: the Lp(a)FRONTIERS APHERESIS trial
Scientific Publications & Presentations
Built on decades of scientific leadership, Ionis continues to advance the understanding of disease through groundbreaking research and innovation. Explore select publications across our therapeutic areas and technologies to better understand the science behind our medicines and pipeline.
Showing 13-24 out of 34 results
Cardiometabolic Disease
Olezarsen for Managing Severe Hypertriglyceridemia and Pancreatitis Risk
Other Medicines
Donidalorsen Treatment of Hereditary Angioedema in Patients Previously on Long-Term Prophylaxis
Cardiometabolic Disease
Targeting APOC3 with Olezarsen in Moderate Hypertriglyceridemia
Cardiometabolic Disease
Olezarsen Data Presented at the ESC Congress 2025 & World Congress of Cardiology
Cardiometabolic Disease
Pelacarsen Data Presented at the Congress of the European Society of Cardiology
Cardiometabolic Disease
Plasma reduction of apolipoprotein C-III with olezarsen leads to significant reductions in postprandial triglyceride levels: Results from a randomized trial
Cardiometabolic Disease
Patient experience with familial chylomicronemia syndrome before and after olezarsen treatment: Qualitative interviews with clinical trial participants
Other Medicines
Bepirovirsen Data Presented at EASL 2025
Cardiometabolic Disease
Design and Rationale of Lp(a)HORIZON Trial: Assessing the Effect of Lipoprotein(a) Lowering With Pelacarsen on Major Cardiovascular Events in Patients With CVD and Elevated Lp(a)
Other Medicines
Donidalorsen Data Presented at the American Academy of Allergy, Asthma, and Immunology/World Allergy Organization Joint Congress
Cardiometabolic Disease
Development and validation of clinical criteria to identify familial chylomicronemia syndrome (FCS) in North America